Search Results - "Naigeon, M."

Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients by Charrier, M., Mezquita, L., Lueza, B., Dupraz, L., Planchard, D., Remon, J., Caramella, C., Cassard, L., Boselli, L., Reiners, K.S., Pogge von Strandmann, E., Rusakiewicz, S., Ferrara, R., Duchemann, B., Naigeon, M., Pignon, J.P., Besse, B., Chaput, N.

“…Innate immunity represents the first step of activation of the immune system and dictates the quality of adaptive immune responses. Studies have reported links…”
Get full text

Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO) by Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Medhi, J., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., Aboubakar, F., Hendriks, L., Planchard, D., Caramella, C., Remon, J., Ngocamus, M., Nicotra, C., Besse, B., Chaput, N.

Get full text

Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts) by Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Medhi, J.J., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., Hendriks, L., Planchard, D., Caramella, C., Remon-Masip, J., Sangaletti, S., Garassino, M.C., Besse, B., Chaput, N.

Get full text

1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study by Rainho, L.T., Albiges, L., Flippot, R., Ajuria, L. Carril, Dalban, C., Escudier, B., Naigeon, M., Desnoyer, A., Teixeira, M., Chaput-Gras, N.

Get full text

11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature by Naigeon, M., de Oliveira, C., Danlos, F-X., Duchemann, B., Saulnier, P., Boselli, L., Jouniaux, J-M., Griscelli, F., Marabelle, A., Lacroix, L., Cassard, L., Besse, B., Chaput, N.

Get full text

1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs) by Benitez, J.C., Naigeon, M., Lambotte, O., De Montpreville, V.T., Mussot, S., Mercier, O., Fadel, E., Scoazec, J-Y., Planchard, D., Lavaud, P., Abdayem, P., Naltet, C., Barlesi, F., Soria, J-C., Saada, V., Chaput, N., Besse, B.

Get full text

1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients by Naigeon, M., de Oliveira, C., Danlos, F-X., Duchemann, B., Boselli, L., Farhane, S., Messayke, S., Bedouda, L., Mohamed-Djalim, C., Griscelli, F., Marabelle, A., Cassard, L., Besse, B., Chaput, N.

Get full text

NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab by Ajuria, L. Carril, Naigeon, M., Dalban, C., Desnoyer, A., Rioux-Leclercq, N., Sautes-Fridman, C., Meylan, M., Vano, Y., Beuselinck, B., Chouaib, S., de Oliveira, C., Tantot, Olivier, Escudier, B., Albiges, L., Chaput, N.

Get full text

687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab by Carril Ajuria, L., Naigeon, M., Dalban, C., Desnoyer, A., Rioux-Leclercq, N., Sautès-Fridman, C., Meylan, M., Vano, Y., Beuselinck, B., Chouaib, S., de Oliveira, C., Tantot, F., Escudier, B., Albiges, L., Chaput, N.

Get full text

1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC by Dall'Olio, F.G., C. Garcia, Bettaieb, A., Naigeon, M., Facchinetti, F., Danlos, F-X., Caramella, C., Benitez, J.C., Aldea, M., Blanc-Durand, F., Naltet, C., Abdayem, P., Lavaud, P., Ghigna, M.R., Chaput, N., Marabelle, A., Planchard, D., Barlesi, F., Soria, J-C., Besse, B.

Get full text

23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma by Flippot, R., Teixeira, M., Roblin, E., Ajuria, L. Carril, Naigeon, M., Rainho, L.T., Cassard, L., Danlos, F-X., Escudier, B., Albiges, L., Chaput-Gras, N.

Get full text

23PImmunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts) by Ferrara, R, Naigeon, M, Auclin, E, Duchemann, B, Cassard, L, Medhi, J J, Boselli, L, Grivel, J, Desnoyer, A, Mezquita, L, Hendriks, L, Planchard, D, Caramella, C, Remon-Masip, J, Sangaletti, S, Garassino, M C, Besse, B, Chaput, N

Get full text

1416PImmunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO) by Ferrara, R, Naigeon, M, Auclin, E, Duchemann, B, Cassard, L, Medhi, J, Boselli, L, Grivel, J, Desnoyer, A, Mezquita, L, Aboubakar, F, Hendriks, L, Planchard, D, Caramella, C, Remon, J, Ngocamus, M, Nicotra, C, Besse, B, Chaput, N

Get full text

184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study by Ajuria, L. Carril, Naigeon, M., Flippot, R., Dalban, C., Desnoyer, A., Rioux-Leclercq, N., Sautes-Fridman, C., Meylan, M., Vano, Y., Beuselinck, B., Chouaib, S., de Oliveira, C., Tantot, F., Escudier, B., Chaput-Gras, N., Albiges, L.

Get full text

20P Human virome epitope-level antiviral antibody profiling identified the cytomegalovirus (CMV) as the main driver of senescent immune phenotype (SIP) in patients with advanced non-small cell lung cancer (aNSCLC) by Naigeon, M., Roulleaux Dugage, M., Danlos, F-X., De Oliveira, C., Boselli, L., Jouniaux, J-M., Griscelli, F., Marabelle, A., Cassard, L., Roman, G., Hulett, T., Besse, B., Chaput-Gras, N.

Get full text